Drug intelligence / Profile preview

LS-SM-001

Development stage: Preclinical
Lead developer: Shanghai Lishan Biopharmaceutical
Modality: Small Molecules, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
Administration: Parenteral

Overview

LS-SM-001 is a preclinical-stage small molecule agonist of the pregnane X receptor (PXR), developed by Shanghai Lishan Biopharmaceutical for the treatment of ulcerative colitis (UC). The compound was identified using a microbial mimetic platform to optimize efficacy and minimize toxicity. LS-SM-001 is formulated using lipid nanoparticle (LNP) drug delivery technology to enable precise, stable release and long-term relief of intestinal inflammation. Activation of PXR by LS-SM-001 inhibits the NF-κB pathway, regulates the expression of inflammation-related genes, and helps restore intestinal homeostasis.

Targets

PXR (Pregnane X receptor)

Beyond the preview

Go deeper on LS-SM-001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LS-SM-001.